Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients With Nonmetastatic Muscle-Invasive Bladder Cancer: Results of the GETUG-AFU V05 VESPER Trial | Journal of Clinical ...
Open-label phase II to evaluate the efficacy of NEoadjuvant dose-dense MVAC In cOmbination with durvalumab and tremelimumab in muscle-invasive urothelial carcinoma: NEMIO - ScienceDirect
A practical approach to bladder preservation with hypofractionated radiotherapy for localised muscle-invasive bladder cancer - Clinical and Translational Radiation Oncology
Avelumab as neoadjuvant therapy in patients with urothelial non-metastatic muscle invasive bladder cancer: a multicenter, randomized, non-comparative, phase II study (Oncodistinct 004 - AURA trial) | BMC Cancer | Full Text
Randomized Phase III Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin, or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients with Muscle-invasive Bladder Cancer. Analysis of the GETUG/AFU V05 VESPER Trial ...
Neoadjuvant chemotherapy with dose dense MVAC is associated with improved survival after radical cystectomy compared to other cytotoxic regimens: A tertiary center experience | PLOS ONE
Bladder cancer
ESMO 2021: GETUG/AFU VESPER V05 Phase III Trial of Dose Dense Methotrexate, Vinblastine, Doxorubicin and Cisplatin or Gemcitabine and Cisplatin As Perioperative Chemotherapy for Patients With MIBC
Comparison of clinical outcomes in patients with localized or locally advanced urothelial carcinoma treated with neoadjuvant chemotherapy involving gemcitabine–cisplatin and high dose-intensity MVAC | SpringerLink
Neoadjuvant Dose Dense MVAC versus Gemcitabine and Cisplatin in Patients with cT3-4aN0M0 Bladder Cancer Treated with Radical Cys
Selecting and Sequencing Therapy in Advanced Urothelial Carcinoma: Navigating a Dynamic Landscape
1438-Bladder/Urothelial neoadjuvant MVAC (methotrexate vinBLASTine DOXOrubicin ciSplatin) SUPERSEDED | eviQ
1616-Bladder/Urothelial neoad ddMVAC (dd methotrexate vinBLASTine DOXOrubicin ciSplatin) | eviQ
GETUG on Twitter: "VESPER (NCT01812369) phase III trial in bladder cancer comparing cisplatin-gemcitabine and dose-dense MVAC in perioperative setting. Preliminary results at ASCO GU 2020 https://t.co/kpjFOQLmap" / Twitter
Randomized phase III trial of dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin, or Gemcitabine and Cisplatin as perioperative chemotherapy for patients with MIBC. Analysis of the GETUG/AFU V05 VESPER Trial Secondary Endpoints -
Significant PFS Improvement at 3 Years with Neoadjuvant dd-MVAC
Understanding Systemic Chemotherapy Options in Bladder Cancer Part II: Chemotherapy Candidacy & Side Effects
ESMO 2021: VESPER Trial Indicates Neoadjuvant Dose-Dense MVAC May be Practice-Impacting in Muscle Invasive Bladder Cancer. | PracticeUpdate
Pierre Blanchard, MD on Twitter: "PRACTICE CHANGING @GETUG_Unicancer TRIAL FOR BLADDER CANCER at #ESMO21 Dose dense MVAC improves PFS & OS over Gem-Cisplatin as periop treatment (neoadj 89%; adj 11%) chemo in
Randomized Phase III Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin, or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients with Muscle-invasive Bladder Cancer. Analysis of the GETUG/AFU V05 VESPER Trial ...
Urothelial Carcinoma: Muscle-Invasive and Metastatic Disease | MDedge Hematology and Oncology
Treatment Administration Schedule: Dose-Dense MVAC (every 14 days for... | Download Table
Urothelial Carcinoma: Muscle-Invasive and Metastatic Disease | MDedge Hematology and Oncology
